Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03158519 · ClinicalTrials.gov registry record · NA

iMETX (Individualized Metabolic RX): a Pilot Study

A NA study, sponsored by Indiana University.

Completed
Registry status
NA
Development phase
64
Enrollment target

NCT03158519 is a NA study that has completed, run by Indiana University. The registered enrollment target is 64 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03158519, a NA study, has completed, sponsored by Indiana University.

COMPLETED
Registry status
NA
Development phase
64 participants
Enrollment target

Study Summary

The purpose of this study is to test the mechanics and feasibility of delivering an individualized intervention to increase physical activity in breast cancer survivors. In this study, researchers will test an intervention that uses a commonly worn activity monitor (i.e., global positioning system \[GPS\] enabled running watch) to see if they can "prescribe" specific ways to increase physical activity that are individually tailored to each participant. The goal is to help participants increase their daily physical activity without having to join a gym or other traditional fitness program. Researchers want to see if they can make specific recommendations (using an application that can be added to a cell phone, tablet and/or computer) on ways participants can slowly increase their activity based upon where they live and work and in a way that is tailored individually to them. For example, participants may be given a route to walk on their lunch break, or new place to park to allow for a longer walk to their job. The goal is to meet participants where they are in their current level of fitness, and to help them think of new and creative ways of increasing activity without the frustration of soreness or risk of injury. As they move more, the recommendations will increase with them.

Interventions

  • BEHAVIORAL iMETX intervention

Trial Details

FieldValue
Enrollment Target 64 participants
Start Date 2017-05-15
Est. Completion 2019-04-01
Phase NA

Sponsor

Indiana University

890 total trials

What the Registry Record Tells You About NCT03158519

The ClinicalTrials.gov registry entry for NCT03158519 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Indiana University, which has 890 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which iMETX intervention is the first listed.

NCT03158519 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03158519 about?

NCT03158519 is a clinical study titled "iMETX (Individualized Metabolic RX): a Pilot Study". The purpose of this study is to test the mechanics and feasibility of delivering an individualized intervention to increase physical activity in breast cancer survivors. In this study, researchers will test an intervention that uses a commonly worn activity monitor (i.e., global positioning system ...

What is the current status of trial NCT03158519?

This trial is currently completed. It is a NA study. The enrollment target is 64 participants. The study started on 2017-05-15. Estimated completion is 2019-04-01.

What interventions are being tested in trial NCT03158519?

The interventions under investigation include: iMETX intervention (BEHAVIORAL).

Who is sponsoring clinical trial NCT03158519?

This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.